Eleison Pharmaceuticals Inc, a drug candidate developer for oncology therapeutics, has filed Form S-1 Registration Statement on January 24, 2022 with the U.S. Securities and Exchange Commission to raise up to $42 million IPO. Pricing terms are yet to announce.
The company focused on developing drug candidates for “orphan” oncology indications that potentially address areas of high unmet medical need in the treatment of cancer. Their strategy is to acquire late-stage compounds to pursue a lower cost and accelerated development pathway.
The Princeton, New Jersey-based company was founded in 2009 and booked $1 million in licensing revenue for the 12 months ended September 30, 2021. It plans to list on the Nasdaq under the symbol “ELSN.” ThinkEquity is the underwriter of the IPO.
The company engages Kurzman Eisenberg Corbin & Lever, LLP as US Securities Counsel, and WithumSmith+Brown, PC as Independent Auditor.
#ipo #Nasdaq #EleisonPharmaceuticals #ELSN #cancer #oncology #drug
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected]